Milestone Scientific Announces Recent Presentations Featuring The Wand STA

Milestone Scientific (NYSE:MLSS) a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that Dr. Glassman, Chief Dental Officer for Dental and Dr. Eugene Casagrande, Director of International & Professional Relations, presented The Wand computer assisted anesthesia system and provided a hands-on demonstration at the Endodontics Solutions Program, a four day endodontics seminar in Toronto, Canada from November 1-4 2018.

As quoted in the press release:

Dr. Casagrande commented, “We received positive feedback to the recent presentations and hands-on demonstrations featuring The Wand, which reinforces our confidence in the market potential for The Wand. These seminars and presentations are part of our continued outreach efforts, focused on both current and next generation dentists.  When trained in the use of The Wand, younger dentists and dental students have the potential to become lifetime users and advocates of the technology.”

The Company also announced that on November 20, 2018, it received a letter from NYSE American LLC (“NYSE American” or the “Exchange”) stating that it is not in compliance with the continued listing standards as set forth in Section(s) 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide (the “Company Guide”).  In order to maintain its listing, the Company must submit a plan of compliance by December 20, 2018 addressing how it intends to regain compliance with Section(s) 1003(a)(i), (ii) and (iii) of the Company Guide by May 20, 2020.  If the plan is accepted, the Company may be able to continue its listing but will be subject to periodic reviews by the Exchange.  If the plan is not accepted or if it is accepted but the Company is not in compliance with the continued listing standards by May 20, 2020, or if the Company does not make progress consistent with the plan, the Exchange will initiate delisting procedures as appropriate. The Company’s management is pursuing options to address the deficiency and intends to submit a compliance plan on or before the deadline set by the Exchange.

Click here to read the full press release.